Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer
1Hematology/Oncology, Denver Health Medical Center, University of Colorado, Denver, Colorado 80224, USA. Shou-ching.tang@dhha.org
Cancer Investigation
|February 25, 2009
Summary
Taxanes improve survival in early breast cancer treatment when combined with anthracyclines. Strategies are being explored to reduce taxane-related toxicities, particularly hematological side effects, for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Taxanes are effective tubulin-targeting agents for breast cancer.
- Their distinct toxicity profile allows combination with anthracyclines in adjuvant therapy.
- Early clinical trials show taxane-anthracycline combinations improve survival in early breast cancer.
Purpose of the Study:
- To review safety issues of taxanes in adjuvant early breast cancer treatment.
- To discuss strategies for mitigating taxane-induced toxicities.
- To explore future research directions for taxanes in early breast cancer.
Main Methods:
- Review of mature data from early randomized clinical trials.
- Analysis of strategies to decrease taxane toxicities.
- Discussion of novel taxane development and molecular marker research.
Main Results:
- Taxane-anthracycline combinations demonstrate a clear survival benefit.
- Increased toxicities, especially hematological, are associated with these combinations.
- Strategies like optimized dosing, sequential therapy, growth factor support, and anthracycline removal show encouraging results in reducing toxicity.
Conclusions:
- Taxanes offer a survival advantage in early breast cancer adjuvant therapy.
- Managing taxane-related toxicities is crucial for optimizing treatment.
- Ongoing research focuses on novel taxanes and predictive markers to improve safety and efficacy.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...